LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announces the appointment of Peter Juul Madsen as Vice President of Chemistry, Manufacturing and Controls (CMC).
Peter Juul Madsen, MSc, has more than 25 years’ experience in managing CMC and manufacturing operations from early preclinical programs to late-stage BLA filings. He started his career at Novo Nordisk and since has been working in various senior positions within CMC and product development in the biotech industry. Peter has broad knowledge in manufacturing of biological products in different expressions systems previously supporting companies including Lundbeck, Genmab, and Zealand Pharma. Peter is joining Prokarium from Cantargia where he was responsible for CMC as Vice President and Head of CMC. Peter has a M.Sc. in Chemical Engineering from the Technical University of Denmark.
Kristen Albright, PharmD, Chief Executive Officer of Prokarium, commented: “The team and Board are delighted to have Peter join at this critical stage as we drive forward our first microbial immunotherapy for non-muscle invasive bladder cancer (NMIBC) into the clinic in 2023. Peter brings a wealth of experience and senior leadership across different technologies and will be an invaluable operational asset as Prokarium advances our innovative immunotherapy pipeline”.
“Leading the manufacturing operations at Prokarium is a unique opportunity to work at the intersection of immunology and synthetic biology in the promising new field of microbial immunotherapy,” said Peter Juul Madsen, Vice President CMC of Prokarium. “I am joining the Prokarium team at an exciting time and I look forward to being part of the next generation of cancer medicines and Prokarium’s growing pipeline”.
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
For enquiries, please contact: